Rapid completion of the human genome was made possible by advances in DNA sequencers. Egea Biosciences Inc. believes that it is taking the next step with an automated technology for the rapid, automated construction of synthetic genes and proteins.

Egea also plans to use its synthesis technology to study protein networks, pathways, genomes and even whole organisms. "We see ourselves as the biological design company," said CEO Glen Evans.